Rodríguez-Lozano AL

Language: Spanish
References: 21
Page: 319-322
PDF size: 300.54 Kb.

ABSTRACT

Access and administration of gamma globulin is not an extraordinary situation nowadays, however the development of the molecule as we know it, has been long and complicated process, since the discovery of antitoxins, by von Behring and Kitasato and the first evidence of antibodies by Ehrlich, it has followed a complicated in order to provide in order to provide the patients an effective and secure product at the same time. A very important step in the history of gamma globulin was the discovery in 1952 by General Bruton when he administered gamma globulin to an 8 years old boy, thereby reducing his infectious processes. Curiously in a 12 years old patient with purpura and hypogammaglobulinemia secondary to immunosuppressive therapy, a dramatic increase in platelets was observed following the gamma globulin administration, resulting in the use of gamma globulin also in autoimmune phenomena, since 1980. Currently on the market exist intravenous presentations 5, 10 and 20% and subcutaneous 16.5%, which have improved significantly the time spent by children in hospital, and some of them benefit from home administration.

REFERENCES

1. Iglesias-Gamarra A, Siachoque H, Pons-Estel B, Restrepo JF, Quintana G, Gómez-Gutiérrez A. Historia de la autoinmunidad. Primera parte. La inmunología ¿desde dónde y hacia dónde? Revista Colombiana Reumatología. 2009;16:11-31.

2. Browning CH. Emil Behring and Paul Ehrlich. Their contributions to science. Nature. 1955;175:570-575.

3. Dale H. Paul Ehrlich, born March 14, 1854. British Med J. 1954;1:659-663.

4. McKhann CF, Green AA, Coady H. Factors influencing the effectiveness of placental extract in the prevention and modification of measles. Journal Pediatr. 1935;6:603-614.

5. Conh EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. Chemical, clinical and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417-432.

6. http://history.amedd.army.mil/booksdocs/wwii/blood/chapter13. htm

7. Stokes J, Maris EP, Gellis SS. Chemical, clinical and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (Human Immune Serum Globulin) in the prophylaxis and treatment of measles. J Clin Invest. 1944;23:531-540.

8. Strokes J, Maris EP, Gellis SS. Chemical, clinical and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. J Clin Invest. 1944;23:531-540.

9. Bruton O. Agammaglobulinemia. Pediatrics. 1952;9:722-728.

10. Dwyer JM. Thirty years of supplying the missing link. Am J Med. 1984;76:46-52.

11. Janeway CA, Merler E, Rosen F, Salmon S, Crain JD. Intravenous gamma globulin–metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med. 1968;278:919-923.

12. Schroeder DD, Dumas ML. A preparation of modified immune serum globulin (human) suitable for intravenous administration: Further characterization and comparison with pepsin-treated intravenous gamma globulin. Am J Med. 1984;76:33-39.

13. Fujita S, Nishida M, Saki T, Yabushita S. Lyophilized native gamma globulin preparation for intravenous administration. 1978. Patent number US 4168303 A.

14. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460- 1480.

15. Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous Immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979;36:237-243.

16. Imbach P, d’Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Baumgartner C, Morell A, Schöni M, Wagner HP. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;317:1228-1231.

17. Imbach P. Historical Review. Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;119:894-900.

18. Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang. 2003;84:193-201.

19. Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham- Rundles CH, Fireman P, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, 10% (Gamunex, 10%). Vox Sang. 2003;84:202-210.

20. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaenous immunoglobulin: opportunities and outlook. J Translational Immunol. 2009;158:51-59.

21. Kobrynsi L. Subcutaneous immunoglobulin therapy, a new option for patients with primary immunodeficiency diseases. Biologics: Targets Ther. 2012;6:277-287.